EASL 2013

infohep news

• Interferon treatment for HBV

  Asian and Caucasian patients respond similarly to pegylated interferon for chronic hepatitis B

  Keith Alcorn / 20 May 2013

  Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at ...

• Treatment in liver transplanted

  Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common

  Liz Highleyman / 17 May 2013

  Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at ...

• Interferon-free regimens

  ACH-3102 and sovaprevir show potent activity, high barrier to resistance in early studies

  Keith Alcorn / 14 May 2013

  Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented ...

• Triple therapy

  Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis

  Liz Highleyman / 13 May 2013

  The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ...

• Interferon-free regimens

  Daclatasvir plus interferon-based therapy cures more genotype 2/3 hepatitis C patients

  Liz Highleyman / 07 May 2013

  Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, ...

• Antiviral therapy

  Truvada works best for immune-tolerant hepatitis B patients, but do they need treatment?

  Liz Highleyman / 07 May 2013

  A combination of tenofovir and emtricitabine (the drugs in the combination pill Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over four years for people with inactive or immune-tolerant disease, ...

• Finance, funding & health economics

  Early hepatitis C treatment may not be cost-saving in France - but early diagnosis will save money

  Keith Alcorn / 07 May 2013

  Treating hepatitis C earlier than recommended by current French and European treatment guidelines, before the development of severe liver fibrosis, may not result in substantial cost savings even if the price of direct-acting ...

• Interferon-free regimens

  Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination

  Liz Highleyman / 02 May 2013

  An all-oral regimen containing three next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a ...

• Triple therapy

  Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C

  Keith Alcorn / 01 May 2013

  A second-generation hepatitis C protease inhibitor, faldaprevir, cured up to 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Peter Ferenci ...

• Triple therapy

  Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%

  Keith Alcorn / 01 May 2013

  A second-generation hepatitis C protease inhibitor, simeprevir, cured around 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Michael Manns of ...